|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
under 75
|
|
|
|
|
|
|
|
EORTC-40924
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 79
|
|
|
|
|
|
|
|
FRE-FNCLCC-95009 EU-96026
|
|
|
|
|
|
|
|
Last Modified: 1/1/2000  First Published: 6/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III, Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 70
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
SPRI-C98-026 SPRI-C98-026-054, SPRI-I98-026
|
|
|
|
|
|
|
|
Last Modified: 5/4/2007  First Published: 1/1/1994 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
70 and under
|
|
|
|
NCI
|
|
|
|
SWOG-9321 CLB-9312, E-S9321, INT-0141, NCT00002548
|
|
|
|
|
|
|
|
Last Modified: 11/30/2007  First Published: 4/1/1994 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
E-5A93 NCT00002556, E5A93
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
any age
|
|
|
|
NCI
|
|
|
|
MSKCC-94004 E-2894, NCI-T93-0198D, T93-0198
|
|
|
|
|
|
|
|
Last Modified: 5/8/2007  First Published: 11/1/1994 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
under 65
|
|
|
|
|
|
|
|
MRC-LEUK-MYEL-VII EU-94030, NCT00002599
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
Pharmaceutical / Industry
|
|
|
|
SPRI-C94-105/I94-105 SCH-C94-105, SCH-I94-105, NCI-V95-0665
|
|
|
|
|
|
|
|
Last Modified: 5/8/2007  First Published: 5/1/1996 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 to 75
|
|
|
|
|
|
|
|
EORTC-30951 NCT00002737
|
|
|
|
|
|
|
|
Last Modified: 8/2/2007  First Published: 6/1/1996 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
16 to 75
|
|
|
|
|
|
|
|
EORTC-18952 NCT00002763
|
|
|
|